Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway

Authors: Wenjun Zhang, Hua Jiang, Jianlin Zhang, Yinfan Zhang, Antang Liu, Yaozhong Zhao, Xiaohai Zhu, Zihao Lin, Xiangbin Yuan

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Liver X receptors (LXRs) are nuclear receptors that function as ligand-activated transcription factors regulating lipid metabolism and inflammation. Recent discoveries found LXRs could regulate tumor growth in a variety of cancer cell lines. In this study, we investigated the effect of LXR activation on melanoma cell proliferation and apoptosis both in vitro and in vivo. Treatment of B16F10 and A-375 melanoma cells with synthetic LXR agonist T0901317 significantly inhibited the proliferation of melanoma cells in vitro. Meanwhile, T0901317 induced the apoptosis of B16F10 melanoma cells in a dose-dependent manner. Furthermore, western blot assay showed that the pro-apoptotic effect of T0901317 on B16F10 melanoma cells was mediated through caspase-3 pathway. Oral administration of T0901317 inhibited the growth of B16F10 melanoma in C56BL/6 mice. Altogether, this study demonstrates the critical role of LXRs in the regulation of melanoma growth and presents the LXR agonist T0901317 as a potential anti-melanoma agent.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PloS One. 2013, 8 (2): e56824-10.1371/journal.pone.0056824.CrossRefPubMedCentralPubMed Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A: miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PloS One. 2013, 8 (2): e56824-10.1371/journal.pone.0056824.CrossRefPubMedCentralPubMed
3.
go back to reference Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, D'Orazio A, Rainaldi S, Vacca M, Mangia A, Palasciano G, Moschetta A: Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology. 2013, 144 (7): 1497-1507. 10.1053/j.gastro.2013.02.005.CrossRefPubMed Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, D'Orazio A, Rainaldi S, Vacca M, Mangia A, Palasciano G, Moschetta A: Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology. 2013, 144 (7): 1497-1507. 10.1053/j.gastro.2013.02.005.CrossRefPubMed
4.
go back to reference Chuu CP, Kokontis JM, Hiipakka RA, Liao S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. Br J Biomed Sci. 2007, 14 (5): 543-553. 10.1007/s11373-007-9160-8.CrossRef Chuu CP, Kokontis JM, Hiipakka RA, Liao S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. Br J Biomed Sci. 2007, 14 (5): 543-553. 10.1007/s11373-007-9160-8.CrossRef
5.
go back to reference Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM: Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. Eur J Med Chem. 2002, 45 (10): 1963-1966. 10.1021/jm0255116.CrossRef Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM: Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. Eur J Med Chem. 2002, 45 (10): 1963-1966. 10.1021/jm0255116.CrossRef
6.
go back to reference Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S: Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther. 2008, 327 (2): 332-342. 10.1124/jpet.108.142687.CrossRefPubMedCentralPubMed Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S: Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther. 2008, 327 (2): 332-342. 10.1124/jpet.108.142687.CrossRefPubMedCentralPubMed
7.
go back to reference Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B: Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14 (22): 2831-2838. 10.1101/gad.850400.CrossRefPubMedCentralPubMed Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B: Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14 (22): 2831-2838. 10.1101/gad.850400.CrossRefPubMedCentralPubMed
8.
go back to reference Raina A, Kaul D: LXR-alpha genomics programmes neuronal death observed in Alzheimer's disease. Apoptosis. 2010, 15 (12): 1461-1469. 10.1007/s10495-010-0541-5.CrossRefPubMed Raina A, Kaul D: LXR-alpha genomics programmes neuronal death observed in Alzheimer's disease. Apoptosis. 2010, 15 (12): 1461-1469. 10.1007/s10495-010-0541-5.CrossRefPubMed
9.
go back to reference Chuu CP, Lin HP: Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res. 2010, 30 (9): 3643-3648.PubMed Chuu CP, Lin HP: Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res. 2010, 30 (9): 3643-3648.PubMed
10.
go back to reference Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S: Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004, 64 (21): 7686-7689. 10.1158/0008-5472.CAN-04-2332.CrossRefPubMed Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S: Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004, 64 (21): 7686-7689. 10.1158/0008-5472.CAN-04-2332.CrossRefPubMed
11.
go back to reference Pommier AJ, Alves G, Viennois E, Bernard S, Communal Y, Sion B, Marceau G, Damon C, Mouzat K, Caira F, Baron S, Lobaccaro JM: Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene. 2010, 29 (18): 2712-2723. 10.1038/onc.2010.30.CrossRefPubMed Pommier AJ, Alves G, Viennois E, Bernard S, Communal Y, Sion B, Marceau G, Damon C, Mouzat K, Caira F, Baron S, Lobaccaro JM: Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene. 2010, 29 (18): 2712-2723. 10.1038/onc.2010.30.CrossRefPubMed
12.
go back to reference Johnson DB, Sosman JA: Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013, 14 (2): 280-292. 10.1007/s11864-013-0226-8.CrossRefPubMed Johnson DB, Sosman JA: Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013, 14 (2): 280-292. 10.1007/s11864-013-0226-8.CrossRefPubMed
13.
go back to reference Mihic-Probst D, Beer M: [Insights into melanoma from a pathologist's perspective]. Praxis. 2013, 102 (4): 219-224. 10.1024/1661-8157/a001190.CrossRefPubMed Mihic-Probst D, Beer M: [Insights into melanoma from a pathologist's perspective]. Praxis. 2013, 102 (4): 219-224. 10.1024/1661-8157/a001190.CrossRefPubMed
14.
go back to reference Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR: Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci. 2012, 33 (7): 394-404. 10.1016/j.tips.2012.03.013.CrossRefPubMed Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR: Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci. 2012, 33 (7): 394-404. 10.1016/j.tips.2012.03.013.CrossRefPubMed
15.
go back to reference Collins JL: Therapeutic opportunities for liver X receptor modulators. Curr Opin Drug Discov Devel. 2004, 7 (5): 692-702.PubMed Collins JL: Therapeutic opportunities for liver X receptor modulators. Curr Opin Drug Discov Devel. 2004, 7 (5): 692-702.PubMed
16.
go back to reference Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR: Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol. 2006, 126 (2): 386-392. 10.1038/sj.jid.5700046.CrossRefPubMed Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR: Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol. 2006, 126 (2): 386-392. 10.1038/sj.jid.5700046.CrossRefPubMed
17.
go back to reference Chang KC, Shen Q, Oh IG, Jelinsky SA, Jenkins SF, Wang W, Wang Y, LaCava M, Yudt MR, Thompson CC, Freedman LP, Chung JH, Nagpal S: Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol. 2008, 22 (11): 2407-2419. 10.1210/me.2008-0232.CrossRefPubMed Chang KC, Shen Q, Oh IG, Jelinsky SA, Jenkins SF, Wang W, Wang Y, LaCava M, Yudt MR, Thompson CC, Freedman LP, Chung JH, Nagpal S: Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol. 2008, 22 (11): 2407-2419. 10.1210/me.2008-0232.CrossRefPubMed
18.
go back to reference Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO: LXRalpha enhances lipid synthesis in SZ95 sebocytes. J Invest Dermatol. 2008, 128 (5): 1266-1272. 10.1038/sj.jid.5701134.CrossRefPubMed Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO: LXRalpha enhances lipid synthesis in SZ95 sebocytes. J Invest Dermatol. 2008, 128 (5): 1266-1272. 10.1038/sj.jid.5701134.CrossRefPubMed
19.
go back to reference Kumar R, Parsad D, Kaul D, Kanwar AJ: Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo?. Exp Dermatol. 2010, 19 (1): 62-64. 10.1111/j.1600-0625.2009.00940.x.CrossRefPubMed Kumar R, Parsad D, Kaul D, Kanwar AJ: Liver X receptor expression in human melanocytes, does it have a role in the pathogenesis of vitiligo?. Exp Dermatol. 2010, 19 (1): 62-64. 10.1111/j.1600-0625.2009.00940.x.CrossRefPubMed
20.
go back to reference Lee CS, Park M, Han J, Lee JH, Bae IH, Choi H, Son ED, Park YH, Lim KM: Liver X receptor activation inhibits melanogenesis through the acceleration of ERK-mediated MITF degradation. J Invest Dermatol. 2013, 133 (4): 1063-1071. 10.1038/jid.2012.409.CrossRefPubMed Lee CS, Park M, Han J, Lee JH, Bae IH, Choi H, Son ED, Park YH, Lim KM: Liver X receptor activation inhibits melanogenesis through the acceleration of ERK-mediated MITF degradation. J Invest Dermatol. 2013, 133 (4): 1063-1071. 10.1038/jid.2012.409.CrossRefPubMed
Metadata
Title
Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway
Authors
Wenjun Zhang
Hua Jiang
Jianlin Zhang
Yinfan Zhang
Antang Liu
Yaozhong Zhao
Xiaohai Zhu
Zihao Lin
Xiangbin Yuan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-16

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine